AstraZeneca plc (LON:AZN) Breztri Aerosphere has been approved in the US for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The approval by the US Food and..

AstraZeneca plc (LON:AZN) has announced the US Food and Drug Administration has accepted a supplemental New Drug Application and granted Priority Review for Brilinta for the reduction of subsequent stroke..

AstraZeneca plc (LON:AZN) and MSD Inc., Kenilworth, N.J., US (known as Merck & Co., Inc. inside the US and Canada) have announced that Lynparza has been approved in the European..

AstraZeneca plc (LON:AZN) has announced that selumetinib has been granted orphan drug designation in Japan for the treatment of neurofibromatosis type 1 (NF1), a rare and debilitating genetic disease.1 Selumetinib..

AstraZeneca plc (LON:AZN) has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the..

AstraZeneca PLC (LON:AZN) Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD),..

Detailed results from the Phase III ADAURA trial showed AstraZeneca PLC (LON:AZN) Tagrisso demonstrated a statistically significant and clinically meaningful improvement in disease-free survival in the adjuvant treatment of patients..

AstraZeneca PLC (LON:AZN) and Daiichi Sankyo Company Limited’s Enhertu (trastuzumab deruxtecan) has been granted Orphan Drug Designation in the US for the treatment of patients with gastric cancer, including gastroesophageal junction..

AstraZeneca PLC (LON:AZN) is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations to make the University of Oxford’s..

AstraZeneca PLC (LON:AZN) and MSD Inc., Kenilworth, N.J., US today announced that Lynparza has been approved in the US for patients with homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer...

AstraZeneca PLC (LON:AZN) Bevespi Aeroshere (glycopyronium/formoteral fumarate) has been approved in China as a maintenance treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis..

AstraZeneca PLC (LON:AZN) and Daiichi Sankyo Company, Limited’s Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of patients with HER2-positive unresectable or..

AstraZeneca plc (LON:AZN) Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular death and hospitalisation for heart failure in adults with heart failure with reduced..

AstraZeneca PLC (LON:AZN) and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced further positive results from the Phase III..

AstraZeneca plc (LON:AZN) ADAURA Phase III trial for Tagrisso (osimertinib) in the adjuvant treatment of patients with Stage IB, II and IIIA epidermal growth factor receptor-mutated (EGFRm) non-small cell lung..

AstraZeneca PLC (LON:AZN) Imfinzi (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with standard-of-care chemotherapies,..

AstraZeneca PLC (LON:AZN) Lokelma (sodium zirconium cyclosilicate) has been approved in Japan for the treatment of patients with hyperkalaemia (elevated levels of potassium in the blood). The approval by Japan’s Ministry of..

AstraZeneca plc (LON:AZN) today announced that Lynparza (olaparib) has been granted orphan drug designation (ODD) in Japan for the maintenance treatment of germline BRCA-mutated (gBRCAm) curatively unresectable pancreatic cancer. Lynparza..

AstraZeneca PLC (LON:AZN) has today announced that Imfinzi confirmed a sustained overall survival benefit in final analysis of the Phase III CASPIAN trial in 1st-line extensive-stage small cell lung cancer...

AstraZeneca (LON:AZN) and MSD Inc (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced high-level results from the Phase III GY004 trial, led by NRG..